Key Highlights
- VolitionRx (VNRX) stock experienced a pre-market surge exceeding 70% on Wednesday morning
- The biotech firm achieved isolation of circulating tumor DNA (ctDNA) at greater than 99% purity from patient blood samples
- Their proprietary Capture-Seq™ technology employs a dual-phase approach combining physical sample enrichment with advanced computational analysis
- Blinded study data revealed 49/49 successful cancer identifications in the primary cohort, plus 13/14 in the secondary group
- VolitionRx estimates the addressable market opportunity at roughly $36 billion and has initiated partnership discussions with diagnostic companies
Shares of VNRX skyrocketed over 70% during pre-market hours Wednesday following VolitionRx’s announcement of what the company characterized as a transformative advancement in liquid biopsy capabilities.
According to the company’s statement, researchers successfully extracted circulating tumor-derived DNA (ctDNA) from patient blood specimens at purity levels surpassing 99%. This achievement essentially means that virtually all non-cancerous DNA was eliminated, producing an exceptionally clean tumor DNA sample.
Liquid biopsy technology has historically faced a fundamental obstacle: the vast majority of cell-free DNA circulating in bloodstream originates from normal, healthy cells rather than malignant ones. Isolating a clear cancer signal from this biological background noise has proven extraordinarily challenging. VolitionRx claims its innovative methodology has cracked this problem.
The company’s Capture-Seq™ platform operates through a two-phase mechanism. Initially, it physically concentrates the target material within the sample. Subsequently, sophisticated bioinformatics algorithms eliminate residual interference. According to VolitionRx, this process yields a dataset consisting of more than 99% pure ctDNA.
Jake Micallef, Chief Scientific Officer at VolitionRx, described the achievement as “a world-first.” He explained that CTCF-bound DNA — the particular DNA signature this methodology targets — appears virtually undetectable in plasma from healthy individuals but represents almost entirely cancer-sourced material in oncology patients.
“Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long-term goal of liquid biopsy,” Micallef stated in the company’s announcement.
Performance in Blinded Clinical Studies
VolitionRx disclosed findings from a pair of blinded cohort investigations. Within the initial cohort, the technology successfully identified all 49 cancer cases tested. The secondary cohort showed detection of 13 cancers among 14 samples.
These figures represent preliminary-phase data, and the participant pools remain limited in size. More extensive clinical trials will be required before any potential commercial launch. Additionally, the approach captures only a portion of available ctDNA, meaning certain tumor fragments might escape detection.
The company has submitted an updated research manuscript to Research Square, a preprint repository. This publication has not yet undergone peer review, which represents a critical validation step before findings gain acceptance within the broader scientific establishment.
Commercial Opportunity and Market Positioning
VolitionRx referenced a combined addressable market opportunity valued at approximately $36 billion, spanning both multi-cancer early detection (MCED) applications and minimal residual disease (MRD) surveillance.
According to company representatives, active negotiations are underway with prospective diagnostic licensing collaborators. To date, no formal agreements have been disclosed.
VNRX stock appeared positioned to finish trading above its 100-day moving average for the first occasion since October 8, 2025, assuming pre-market momentum carried through the regular trading session.
The updated preprint manuscript is anticipated to appear on Research Square in the near term, based on the company’s timeline.
